Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations

BACKGROUND: Epidermal growth factor receptor (EGFR) is one of the most common oncogenes in non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitor (TKI) and platinum-doublet chemotherapy (PT) are effective regimens in patients with NSCLC harbouring EGFR mutations. Among these patients, pr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:ESMO Open
Prif Awduron: Shinno, Yuki, Goto, Yasushi, Watanabe, Sho, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2018
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6267457/
https://ncbi.nlm.nih.gov/pubmed/30559979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000399
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg